Browse News
Filter News
Found 8 articles
-
BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases
2/22/2022
BioCryst Pharmaceuticals, Inc. today announced the enrollment of the first patient in the RENEW proof-of-concept basket study with its oral Factor D inhibitor, BCX9930, in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
1/7/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-1 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria (PNH).
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
11/29/2021
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-2 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria (PNH).
-
BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones
11/3/2021
BioCryst Pharmaceuticals, Inc. announced financial results for the third quarter ended September 30, 2021, and provided a corporate update.
-
BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones
8/5/2021
BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2021, and provided a corporate update.
-
BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH
7/15/2021
BioCryst Pharmaceuticals, Inc. announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria.